Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Research advances the field not only through positive findings, but also by answering important clinical questions that help refine treatment strategies and identify areas where further innovation is needed. Every well-conducted study brings us one step closer to improving outcomes and quality of life for our patients.
Grateful to my co-authors, collaborators, research staff, and, most importantly, the patients who participated in this work. Their contributions make progress possible.”
Other articles featuring Narjust Florez on OncoDaily.
